While there are in vivo data showing that statin treatment (atorvastatin and rosuvastatin) reduces tumour growth in mice bearing tumours with mutant p53 [86] and appears to have positive effects in lung cancer patients with somatic p53 mutations [93], there have been no studies assessing the impact of cancer incidence in relevant murine models of LFS. This evidence concerns the gene TP53 and neoplasm.